Schedule & Agenda
Monday, June 5
9:00 AM - 12:00 PM
The Department of Defense (DoD) is continuously engaging in efforts to protect the warfighter from…
1:00 PM - 2:00 PM
The pharma industry is facing a wave of loss of exclusivity estimated at $200B through 2026 and an…
Although the COVID-19 pandemic has accelerated digital transformation, there are still varying…
This panel will discuss the next generation of digital therapeutics and the progress and promise of…
Targeted protein degradation (TPD) is a hot area of drug discovery aiming to expand the universe of…
Hear from biotech and pharma innovators who have created collaborations to turn technology…
To further exploit the full potential of real-world data (RWD) to generate evidence suitable to…
Session Room 204AB
This session will focus on pull incentives (e.g., the PASTEUR Act, BARDA procurements under Project…
The EU pharmaceutical landscape is experiencing its most significant transformation in over 20…
In the words of Eleanor Roosevelt, “A woman is like a teabag—you can’t tell how strong she is until…
2:15 PM - 3:15 PM
Commissioner Califf has on numerous occasions noted combatting misinformation as a high priority…
This session will present strategies from CEOs who have secured major financings (AsherBio $108M…
The COVID-19 and Mpox health emergencies have underscored the need to be prepared to address future…
Join the discussion as to how we can address the healthcare challenges of today and tomorrow by…
In April 2022, FDA issued draft guidance on developing a Race and Ethnicity Diversity Plan to…
The market volatility in the last 18 months has made it difficult for public biopharmaceutical…
Is this the yearIs this the year that biotech IPO's recover? How do you know when to make the leap?…
The clinical development of advanced therapies often proceeds without a robust understanding of the…
Novel enabling technologies (ET) and therapies emerge at an ever-increasing speed across multiple…
3:30 PM - 4:30 PM
Drug approval rates in biotech are dismal, with CNS proving to be a particularly challenging area…
In today’s turbulent market backdrop, both life science companies and investors are required to…
We will dive deep into the challenges faced by biotech companies in securing funding, particularly…
Life sciences and healthcare companies are increasingly leveraging AI, machine learning and data…
COVID-19 lit a fire under global regulatory systems, triggering regulatory bodies and pharma…
Humanity will reach a critical milestone when we can rapidly reprogram and re-engineer biological…
Community-based partnerships are vital to successfully addressing long-standing inequities in the…
How can patient advocacy groups attract an early-stage company to develop technology for their…
Tuesday, June 6
11:00 AM - 12:00 PM
Biotech is a cornerstone to serving the world’s health-related needs for all demographics; but in…
The advent of mRNA vaccines, accelerated by the global SARS-Cov-2 pandemic, marked the beginning of…
The 33rd edition of EY’s Beyond Borders Biotechnology Report offers a chance to take stock of the…
Capital is a critical component for success. Although digital health funding dipped from its peak…
This session will engage an expert panel in a discussion on a number of timely regulatory policy…
Organizations from pharma sponsors, site networks, technology and service providers, advocacy…
Protecting Trade Secrets from the Growing Foreign Influence Threat to Early Stage Discovery Programs
The early discovery stages of the research and development process is the most vulnerable time for…
Over the last decade, there has been an incredible surge in innovation in the life sciences,…
The COVID-19 pandemic highlighted the need for more geographic diversity in the production…
1:45 PM - 2:45 PM
2023 marks the 40th anniversary of the Orphan Drug Act (ODA). Many advances have been made in the…
The Asia-Pacific region outside of Greater China now holds around a quarter of all the world’s new…
The value of biotech companies can best be described as a discontinuous growth function with…
Inequities exist at every phase of the U.S. healthcare system — from clinical research to diagnosis…
The COVID-19 pandemic significantly changed the RNA landscape, with new and exciting technologies…
FDA and sponsors share the goal of productive and timely engagement during drug development. …
A closer look at current legislative initiatives being considered by the Senate Judiciary…
An aggressive drop in the market and the aftermath of two years of deals via Zoom create a unique…
Commitments to diversity, equity, and inclusion in the boardroom have been a priority in the…
Join a distinguished panel of international data privacy & data security experts for the latest…
3:00 PM - 4:00 PM
Over the last 47 years, since the creation of the statutory regulatory framework, we’ve evolved…
While the biotech industry has seen record years of venture investment, crossover investments, and…
For many new therapies, Diversity, Equity, and Inclusion (DEI) is as much a commercial imperative…
The NIH estimates indicate that about 1 in 10 people in the United States have a rare disease, and…
This panel of top-tier biotech CEOs turned VC investors and advisors will discuss their outlook on…
The world is facing a demographic crisis, driven by unhealthy aging: societies across the globe are…
As computational analysis and informatics play an increasingly important role in R&D, biopharma…
How have new understandings of cell biology, genomics, AI/ML based platform technologies expanded…
In the United States, there are two worldclass state-funded and voter approved biomedical research…
4:15 PM - 5:15 PM
Representatives from the Committee on Foreign Investment in the United States (CFIUS) will speak to…
Let’s talk about all the good things and all the bad things that may be when it comes to realizing…
Though the life science industry has made strides in increasing diversity, equity and inclusion …
Data only has value when it is discoverable, shareable, and usable, but most rare disease data…
The Vaccines for Children (VFC) program was established in 1994 to increase access to childhood…
Join us for a robust discussion on the topic of International Regulatory Harmonization in our…
An increasingly vocal group of critics complain that life-sciences patents are holding up…
While academic scientists have always brought to light new insights, these have traditionally been…
Wednesday, June 7
11:00 AM - 12:00 PM
Join us for a special edition of the popular weekly discussion of all things biotech. Reporting…
With growing inflation and economic turmoil, budgets are tighter than ever. Governments and other…
Legislative advocacy is cornerstone to achieving impactful public policy. Many advocacy efforts are…
China’s urge for innovation is strong and has enabled some biotechs to develop first in class and…
The development of cell, gene therapy, and genome editing presents several challenges. While…
Ironically, billions of dollars and FOMO investor zeal frantically chasing the promise of…
The pandemic forced support ecosystems for emerging biotechs to adapt their processes to continue…
Navigating the Neurodegenerative Diseases Labyrinth: Perspectives from Academia, Biotech, and Pharma
Identifying effective treatments for neurodegenerative diseases is challenging given that the…
The Preparedness and Treatment Equity Coalition (PTEC) works across the healthcare sector to bring…
New viruses emerge with ever-increasing frequency; however, we still lack antiviral therapeutics…
1:45 PM - 2:45 PM
The Inflation Reduction Act (IRA) contains some of the most significant changes to prescription…
While research shows that diverse teams perform better, are more creative, and contribute to higher…
The coming wave of gene therapies has already forced biotechs to change their development model…
mThe discovery of antibiotics was one of the biggest medical breakthroughs in the 20th century and…
The human genome contains approximately 30,000 genes. Of these, 6,000+ sites are estimated to have…
The psychedelics industry has evolved from a stigmatized counterculture to a scientifically robust…
This session will review exciting developments in cloud-based submissions which are now a reality…
An alarm is being sounded by patients, caregivers, and providers around the high acuity of distress…
Despite recent strides in medical innovation – in oncology, COVID-19, neurodegenerative disorders…
3:00 PM - 4:00 PM
Are AI-enabled solutions advancing quickly enough to outpace the rapidly evolving mental health…
Academic developers are major contributors to the research and development of cell and gene…
This panel will present comparative views of biopharma, investor-backed, and independent incubators…
The Asia Pacific (APAC) region has become an increasingly attractive location for investments in…
Each year the National Institutes of Health's (NIH) various institutes award over $1.2 billion in…
Respiratory Syncytial Virus (RSV) has long been a global public health focus, representing a…
Hear from leading patient advocates and policy experts on IRA implementation from the patient and…
This panel will discuss the evolving landscape of immunotherapy in solid tumors, with a focus on…
4:00 PM - 5:15 PM
Innovation. Which ideas and inventions are likely to serve as the foundation for the creation of…
4:15 PM - 5:15 PM
As more and more diverse cell therapies are progressing through the pipeline, innovators are…
Leveraging biotechnology innovation will be key to meeting global efforts to combat climate change…
FDA’s Oncology Center of Excellence launched “Project Optimus” in 2021, to encourage sponsors to…
Early to Mid-Stage Biotechs: Creating Partnerships to Enhance Program Value and Accelerate Therapies
Moderated by Drew Armstrong of Endpoints News, this interactive panel discussion aimed at early to…
What do biotech companies need to consider as they develop their global growth strategy? Companies…
COVID-19 is here to stay. With current prevention and treatment strategies, the virus will continue…
The IRA is market-driven. It is changing the US healthcare landscape with new approaches toward…
Brain aging drives devastating neurodegenerative diseases including Alzheimer’s and Parkinson’s,…
Thursday, June 8
9:00 AM - 10:00 AM
The use of patient experience data (PED) to inform the development and benefit-risk assessment of…
Tackling a problem like cancer requires both the ingenuity of small biotech players and the…
Companies are using AI/ML models to make pre-clinical drug development a more streamlined process…
While often evaluated by the modality they employ or therapeutic area in which they focus, a…
The pharma pipeline is brimming with ever more personalized therapies, mutation-specific…
The Cancer Moonshot in Africa: Improving Cancer Patient Outcomes through Public-Private Partnerships
During the recent U.S.-Africa Leaders Summit in December 2022, First Lady Dr. Jill Biden recognized…
Genome Editing therapeutic platforms (e.g. zinc finger nucleases, TALENs, meganucleases) have…
10:15 AM - 11:15 AM
More than 10 years ago, the first immune checkpoint inhibitor (ICI) was approved in a monumental…
Cardiovascular disease is the leading public health issue in the United States, according to the…
Major changes in the diagnostics industry are underway with an increased push to self-testing,…
Next-generation approaches to gene therapy are emerging as one of the most promising areas of drug…
Vaccines are global health’s biggest success, helping people of all ages live longer, healthier…
Health systems are not only the source of scientific innovation that leads to new treatments for…
1:00 PM - 2:00 PM
In vitro diagnostics have seen incredible innovation during the COVID-19 pandemic, and advances in…
Panelists will discuss how to rethink innovation in oncology. Experts will touch on global patient…
In 2020, more than 71% of those with PhDs in health and medical sciences were women, strategically…
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
.png){kind=logo}
